Laboratory Tests to Differentiate PBC, PSC, and Metabolic Fatty Liver Disease
Start with alkaline phosphatase (ALP) and gamma-glutamyltransferase (GGT) to identify cholestatic disease, then use anti-mitochondrial antibody (AMA) testing to definitively distinguish PBC from PSC, while metabolic fatty liver disease typically shows a hepatocellular pattern with normal or mildly elevated ALP/GGT. 1
Initial Screening: Identify the Pattern
Begin with standard liver biochemistry to determine if you're dealing with cholestatic versus hepatocellular disease:
- Cholestatic pattern (PBC and PSC): Elevated ALP + GGT, with or without elevated bilirubin 1
- Hepatocellular pattern (Metabolic fatty liver disease): Elevated ALT/AST with normal or mildly elevated ALP (typically <1.5x upper limit of normal)
Differentiating PBC from PSC: The Critical Tests
Once cholestasis is confirmed, the diagnostic algorithm is straightforward 1:
Anti-Mitochondrial Antibody (AMA)
- Positive AMA = Primary Biliary Cholangitis 1
- AMA is essentially 100% specific for PBC when present
- Usually present in very high titers in PBC 2
- Nearly always negative in PSC 2
Additional Autoantibodies
- Anti-nuclear antibodies (ANA), particularly sp100 and gp210 subtypes, support PBC diagnosis 1
- Perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA): May be present in PSC but is nonspecific 3
- Important caveat: Autoantibodies should NOT be used to diagnose or risk-stratify PSC 1
Serum IgG4
- Elevated IgG4 suggests IgG4-related cholangitis (IRC), which mimics PSC 1
- Should be checked in every patient with large duct sclerosing cholangitis at diagnosis 1
- Helps exclude secondary causes before confirming PSC
Metabolic Fatty Liver Disease: The Distinct Profile
Metabolic fatty liver disease presents with a fundamentally different laboratory pattern:
- Hepatocellular injury: AST/ALT elevation (typically ALT > AST in early disease)
- Minimal cholestasis: ALP and GGT normal or only mildly elevated
- Metabolic markers: Check fasting glucose, lipid panel, hemoglobin A1c
- Negative autoantibodies: AMA, ANA, smooth muscle antibodies all negative
- Normal bilirubin in early stages
The Diagnostic Algorithm
- Elevated ALP + GGT → Proceed with cholestatic workup
- Check AMA + ANA (sp100, gp210)
- Normal ALP/GGT with elevated transaminases → Consider metabolic fatty liver disease
Critical Pitfalls to Avoid
Do not rely on autoantibodies for PSC diagnosis. The 2022 EASL guidelines explicitly state with 100% consensus that autoantibodies should not be used to diagnose or risk-stratify PSC 1. While p-ANCA and other nonspecific antibodies may be present, they add no diagnostic value 3.
Rare PSC patients may have normal ALP/GGT. Some patients present with typical cholangiographic findings but without cholestatic biochemistry elevation 1. These patients require careful follow-up.
Check IgG4 levels in all suspected PSC cases to exclude IgG4-related cholangitis, which requires different treatment (corticosteroids) 1.
Additional Supportive Tests
While not primary differentiators, these tests provide supporting information: